FDA officials say high priority will be given to applications with endpoints that can be leveraged for other rare diseases
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy